A recent study focused attention on whether Alzheimer’s disease can spread from one human to another. The risk remains small as long as standard precautions are followed during surgery and other procedures.
A new blood-based Alzheimer’s screening test, created with a grant from BrightFocus, received a “Breakthrough Device” designation by the FDA. This speeds up its timeline for possible approval and public use.
All mouse models used to represent Alzheimer’s disease are imperfect, and can only approximate how the disease develops in humans. However, a BrightFocus-funded research project is being hailed as a game-changer that could make results highly relevant to human disease.
In 2003, after his mother was diagnosed with Alzheimer’s, Microsoft co-founder Paul Allen put part of his fortune into brain research. What a fitting legacy for an “idea man,” whose philanthropy remains an inspiration.
BrightFocus organized an ARVO 2018 symposium where experts weighed in on exercise, diet, and nutritional supplements for eye health. What research is being done, and are there any benefits for AMD and glaucoma?
The world’s largest vision science meeting is about to begin. ARVO 2018 will showcase BrightFocus leadership and the latest advances in macular degeneration and glaucoma research being from achieved by BrightFocus grantees.
April 26, 2018
Donate to Cure Brain and Eye Diseases
Help end Alzheimer's, Macular Degeneration, and Glaucoma